Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-A10 + AS01B ASCI with Treg depletion in AML
NCT01513109Phase 2Unknown
- Sponsor
- Institut Jules Bordet
- Start
- Dec 2011
- Primary completion
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WT1-A10 + AS01B in acute myeloid leukemia (AML), sponsored by Institut Jules Bordet. Status: unknown.
02
Drugs
WT1-A10 + AS01B
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01513109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513109.